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BACKGROUND: Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected
non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1
(fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment.
MATERIALS AND METHODS: Pre-treatment circulating levels of fIGF-1 were tested in 110 advanced NSCLC patients enrolled in a phase II
study of paclitaxel and carboplatin given alone (PC) or in combination with F at doses of 10 or 20mgkg
 1 (PCF10, PCF20).
RESULTS: Cox proportional hazards model interactions were between 2.5 and 3.5 for fIGF-1 criteria in the 0.5–0.9ngml
 1 range.
Patients above each criterion had a substantial improvement in progression-free survival on PCF20 related to PC alone. Free IGF-1
correlated inversely with IGF binding protein 1 (IGFBP-1, r¼ 0.295, P¼0.005), and the pre-treatment ratio of insulin to IGFBP-1
was also predictive of F clinical benefit. In addition, fIGF-1 levels correlated with tumour vimentin expression (r¼0.594, P¼0.021)
and inversely with E-cadherin (r¼ –0.389, P¼0.152), suggesting a role for fIGF-1 in tumour de-differentiation.
CONCLUSION: Free IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy.
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The insulin growth factor (IGF) system is comprised of the IGF
ligands (IGF-1 and IGF-2), the IGF binding proteins (IGFBPs 1–7)
that regulate ligand bioactivity, the cell surface receptors insulin-
like growth factor type 1 receptor (IGF-IR) and IGF-2R, the
adaptor proteins insulin receptor substrate (IRS)-1 and -2 and
downstream signalling pathways (Pollak, 2008). Signalling through
the IGF-IR plays important roles in normal growth and develop-
ment as well as in the initiation and progression of neoplasia
(Chitnis et al, 2008). There is considerable current interest in
targeting the IGF-1 receptor as a therapeutic strategy in oncology,
with more than a dozen drug candidates undergoing clinical
evaluation (Gualberto and Pollak, 2009). In NSCLC, the IGF-IR has
been shown to be frequently expressed in tumour tissue as well as
to mediate the proliferation of lung cancer cell lines (Favoni et al,
1994). Also, high IGF-1 levels have been associated with
higher incidence and aggressiveness of NSCLC (Spitz et al,
2002). These data suggest that targeting the IGF-IR could be a
viable approach for the treatment of NSCLC.
Figitumumab (F) is a selective inhibitor of the IGF-IR that has
been well tolerated in initial studies (Gualberto, 2010). Figitumu-
mab enhances the tumour growth inhibition of chemotherapy
and targeted agents in pre-clinical models (Cohen et al, 2005).
A recently completed phase II study concluded that F increases the
response rate and progression-free survival (PFS) benefit of
paclitaxel and carboplatin as first-line treatment of patients with
advanced NSCLC (Karp et al, 2009). However, pivotal trials of this
agent in NSCLC were recently discontinued owing to futility. These
results stress the need to identify patient subpopulations that may
preferentially benefit from F therapy. This paper summarises a
series of preliminary ancillary studies conducted to characterise
plasma markers that could identify a subset of patients who derive
benefit from the addition of F to standard NSCLC therapy.
MATERIALS AND METHODS
Patients
Study 1002 was a multiple-centre, open-label, randomised phase II
trial that investigated the efficacy of the combination of F with
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spaclitaxel (P) and carboplatin (C) as treatment for patients with
chemotherapy-naı ¨ve stage IIIB or IV NSCLC (Karp et al, 2009).
Briefly, patients had histologically or cytologically confirmed
NSCLC not amenable to curative treatment. Eligible patients had
at least one unidimensionally measurable lesion according to the
Response Evaluation Criteria in Solid Tumours and Eastern
Cooperative Oncology Group performance status of 0/1. Eligible
patients were randomised 2:1 (PCF arm:PC arm) to receive
P at 200mgm
 2 intravenously (i.v.) over 3h and C with area under
the plasma concentration–time curve of 6, i.v. over 15–60min
every 3 weeks with or without F at doses of 10 or 20mgkg
 1 in two
sequential cohorts (PCF10, PCF20). The protocol was conducted in
accordance with Good Clinical Practice guidelines and was
approved by each participating institutional ethics review boards.
All patients signed written informed consent before enrolment.
Laboratory assessments
Plasma samples were collected from fasted patients before trial
treatments. Levels of total IGF-1, free IGF-1 (fIGF-1), IGF-2,
IGFBP-1, IGFBP-2, IGFBP-3, insulin and cotinine were determined
at a central laboratory (Department of Pathology and Laboratory
Medicine, Brown University, Providence, RI, USA), using the
ELISA method. Antibodies and reagents were from Beckman-
Coulter Diagnostic System Laboratories (Webster, TX, USA) as
follows: total IGF-1 (DSL 10-2800), fIGF-1 (DSL 10-9410), IGF-2
(DSL 10-2600), IGFBP-1 (DSL 10-7810), IGFBP-2 (DLS 10-7100),
IGFBP-3 (DSL 10-6600) and insulin (DSL 10-1610). Cotinine was
determined using a kit (CO096A) from Calbiotech (Spring Valley,
CA, USA). Glucose and creatinine were determined at the local
clinical study sites using standard techniques. E-cadherin and
vimentin were quantified using fluorescent immunohistochemistry
(F-IHC) and an automated analysis system. Briefly, tumour tissues
were deparaffinised, hydrated in water and antigen retrieval
performed using standard techniques. Incubation with primary
antibodies was conducted for 1h at room temperature. Primary
antibodies were mouse anti-E-cadherin (M3612, clone NCH38,
2mgml
 1; Dako, Carpinteria, CA, USA) and mouse anti-vimentin
(MS-129, 0.07mgml
 1; Thermo Scientific, Rockford, IL, USA).
Each primary antibody was included in a cocktail with rabbit
anti-pan-cytokeratin (Z0622, 1:200; Dako) for the identification of
epithelial regions and non-nuclear regions. Image capture, review,
validation and scoring were carried out using a PM2000
epi-fluorescence microscopy system and AQUAnalysis software
(HistoRx, New Haven, CT, USA).
Statistical analysis
Progression-free survival curves were constructed using the
Kaplan–Meier method, and differences analysed by the log-rank
test using the MedCalc software (Mariakerke, Belgium). Receiver-
operating characteristic (ROC) analysis, area under the curve
estimates and significance tests were accomplished using the built-
in functions of MedCalc. Cox proportional hazards regression
analysis was used to determine biomarker interactions. Biomarker
data were analysed using ANOVA and correlations determined
using Pearson’s correlation tests.
RESULTS
Pre-treatment plasma fIGF-1 levels identify NSCLC patients who
may benefit from the addition of F to standard chemotherapy.
A total of 156 patients were randomised 2:1 to receive PC with
or without F at doses of 10 or 20mgkg
 1 (PC, PCF10, PCF20).
Plasma samples were obtained on cycle 1 day 1 before dosing from
110 of these patients. Patients were 68% men and had a median age
of 64 years (range: 36–85). Forty-nine percent of them had
tumours of adenocarcinoma histology and 80% were stage IV.
Thirty-five patients received PC, 40 PCF10 and 35 PCF20. The
overall efficacy results of this trial have been reported previously
(Karp et al, 2009). Patients receiving the PCF20 regimen had a
clinical benefit in terms of PFS of approximately 6 weeks over PC
alone, while no clinical benefit over that of PC alone was observed
with PCF10 (3.53, 3.60, 5.0 months median PFS for PC, PCF10 and
PCF20, respectively, P¼0.015). Median concentrations of baseline
total IGF-1, free IGF-I, total IGF-2, insulin, and IGFBP-1, -2, -3
were, respectively, 219.3, 0.6, 578.1, 23.6, 15.1, 2.3 and
3627.8ngml
 1. Potential biomarker associations with patient
demographics were investigated. Higher baseline levels of fIGF-1
were observed in female patients (0.78ngml
 1, 0.22–1.38 95% CI,
N¼36) than in male patients (0.52ngml
 1, 0.07–1.50 95% CI,
N¼74, P¼0.005), and in patients with tumours of adenocarcino-
ma histology (0.76ngml
 1, 0.13–1.68 95% CI, N¼53) than in
those with other histologies (0.55ngml
 1, 0.06–1.4 95% CI,
P¼0.03). No other differences were identified.
Progression-free survival was estimated in the subset of patients
providing biomarker samples using the Kaplan–Meier method.
Median PFS was similar to that in the overall trial population: 2.97,
3.63 and 5.6 months, respectively, for the PC, PCF10 and PCF20
cohorts (P¼0.002). The ability of pre-treatment biomarker tests
to identify patients who experienced prolonged clinical benefit on
PCF treatment, for example, PFS longer than 6 months, was
investigated using ROC analysis. Receiver operating characteristic
curves plot the true positive rate (sensitivity) in function of the
false positive rate (100-specificity, if expressed as percentage) at
different biomarker cutoff points, and the 95% CI of the value
for the area under the ROC curve (AUC) can be employed to test for
predictive value (ROC curve AUC must be 40.5 for the test to be
potentially useful) (Zweig and Campbell, 1993). Receiver operating
characteristic plots were also employed to screen for markers able
to identify patients with reduced clinical benefit, for example,
patients with PFS shorter than 3 months. Table 1 summarises the
AUC values and significance of the ROC analyses for the base-
line analytes of patients receiving PCF20. As expected, the AUC
95% CI were wide owing to the small sample size (N¼35);
however, it was observed that high pre-treatment levels of fIGF-1
(at least 0.54ngml
 1) in patients receiving PCF20 were associated
(P¼0.007) with PFS 46 months, whereas low pre-treatment
fIGF-1 levels were associated (P¼0.026) with PFS o3 months.
When patients receiving PCF10 and PCF20 were analysed together
(N¼75), significant AUCs (Pp0.05) were also identified. Figure 1
shows the ROC plots for all patients treated with F (10, 20mgkg
 1)
using PFS benefit beyond 3, 4, 5 and 6 months as end points.
Table 1 ROC for baseline IGF-IR-related serum analytes in patients
receiving PCF20
PFS at 3 months PFS at 6 months
Analyte
ROC AUC
95% CI P-value
ROC AUC
95% CI P-value
Total IGF-1 0.368–0.758 0.566 0.476–0.846 0.140
fIGF-1 0.536–0.852 0.026 0.661–0.933 0.007
IGF-2 0.430–0.811 0.290 0.460–0.834 0.215
Insulin 0.387–0.769 0.457 0.464–0.832 0.213
IGFBP-1 0.531–0.880 0.040 0.405–0.784 0.401
IGFBP-2 0.498–0.862 0.086 0.361–0.752 0.650
IGFBP-3 0.306–0.652 0.842 0.478–0.809 0.178
Abbreviations: AUC¼area under the ROC curve; CI¼confidence interval;
IGF¼insulin-like growth factor; fIGF-1¼free insulin-like growth factor 1;
IGFBP¼insulin-like growth factor binding protein; IGF-IR¼insulin-like growth factor
type 1 receptor; PCF¼paclitaxel and carboplatin in combination with figitumumab;
PFS¼progression-free survival; ROC¼receiver operating characteristics.
Free IGF-1 predicts sensitivity to figitumumab
A Gualberto et al
69
British Journal of Cancer (2011) 104(1), 68–74 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sAlthough our sample size was insufficient to investigate differences
in AUC, the results represented in the figure were suggestive
that fIGF-1 is a better predictor of long-term clinical benefit of F
combination therapy. In contrast, pre-treatment fIGF-1 levels were
not predictive of PFS in patients receiving PC only (not shown),
suggesting that this parameter was not a general prognostic
marker for the outcome of chemotherapy. Of interest, high
pre-treatment levels of IGFBP-1 were associated (P¼0.04) with
PFS o3 months (Table 1).
The potential interaction between pre-treatment fIGF-1 criteria
and the PFS benefit derived from F treatment was then investigated
using the Cox proportional hazards models. Free IGF-1 cutoff
criteria from 0.1 to 0.9ngml
 1 were examined. Useful criteria
were found in the range of 0.5–0.9ngml
 1. For PCF20 vs PC, the
estimated treatment–biomarker interaction terms from Cox
proportional hazards models were between 2.5 and 3.5 for fIGF-1
criteria in the 0.5–0.9ngml
 1 range, with one-sided P-values
of 0.11 (0.5ngml
 1 criterion), 0.09 (0.6ngml
 1 criterion), 0.030
(0.7ngml
 1 criterion), 0.033 (0.8ngml
 1 criterion) and 0.026
(0.9ngml
 1 criterion) adjusted for multiple testing. Hazard ratios
for patients with fIGF-1 values above or below the 0.5–0.9ngml
 1
criteria are shown in Figure 2A. Patients above each criterion had a
substantial observed improvement in PFS on the PCF20 arm,
while only a modest effect was observed below the criterion. For
example, the PFS hazard ratio (PCF20/PC) was 4.2 for patients with
fIGF-1 above 0.8ngml
 1, but only 1.9 for patients with fIGF-1
equal or below 0.8ngml
 1. A significant biomarker/treatment
interaction for PCF10 was only observed at the fIGF-1
40.8ngml
 1 (P¼0.027) and 40.9ngml
 1 (P¼0.04) criteria.
Figure 3A–C shows specific examples of Kaplan–Meier curves for
all patients in the biomarker cohort (Figure 3A; N¼110), those
with a baseline fIGF-1 level equal or lower than 0.7ngml
 1
(Figure 3B; N¼64) and those with a baseline fIGF-1 level higher
than 0.7ngml
 1 (Figure 3B; N¼46). Median PFS for patients who
had a baseline fIGF-1 level above 0.7ngml
 1 were 2.63 (PC), 3.97
(PCF10) and 6.53 months (PCF20), respectively (P¼0.0007). In
contrast, no apparent differences in median PFS between the
treatment cohorts were observed in those who had a baseline
fIGF-1 level equal or below 0.7ngml
 1. Additional analysis of PFS
by fIGF-1 quartiles further indicated that clinical benefit of
F combination therapy increased with baseline fIGF-1 levels.
Tumours in patients with plasma fIGF-1 levels at the highest
quartile (4th quartile, fIGF-1 X1ngml
 1) derived particular
benefit from the addition of F to standard chemotherapy (Figure 4).
Effect of the insulin to IGFBP-1 ratio
The findings described above prompted us to investigate the
mechanisms underlying the heterogeneity of fIGF-1 levels among
NSCLC patients. It is well known that the bioactivity of IGF-1 and
IGF-2 is modulated by 6, potentially 7, binding proteins (IGFBPs),
of which IGFBP-1 and -3 are the best characterised (Pollak, 2008).
Using the Pearson’s parametric correlation test, a significant
inverse correlation was identified between pre-treatment fIGF-1
and IGFBP-1 levels (r¼ 0.295, P¼0.005), but no significant
association was observed between fIGF-1 and IGFBP-2 (P¼0.37)
or IGFBP-3 (P¼0.9). Receiver operating characteristic plots were
conducted to investigate potential associations between PFS rate
and the pre-treatment ratios of IGF-1, IGF-2 and insulin to IGFBP-
1, -2 and -3. A high baseline ratio of insulin (mUml
 1) to IGFBP-1
(ngml
 1) was found to be predictive (P¼0.05–0.1) of the PFS rate
of patients receiving PCF20 at multiple time points in the 3–8
months post-treatment period. No other significant associations
were identified.
Insulin/IGFBP-1 ratio cutoffs criteria of 0.6–1 were then
examined using Cox proportional hazards models. For PCF20, all
cutoff criteria appeared to be potentially useful, with one-sided
P-values for treatment–biomarker interaction of 0.07 (insulin/
IGFBP-1 ratio of 0.5), 0.06 (ratio of 0.6), 0.02 (ratio of 0.7), 0.02
0
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Figure 2 (A) Hazard ratio of Study 1002 patients receiving treatment
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 1) vs PC alone according to baseline fIGF-1
levels. (B) A hazard ratio of patients receiving treatment with PCF (10 or
20mgkg
 1) vs PC alone according to baseline insulin to IGFBP-1 ratio.
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Figure 1 Receiver-operating characteristic curves for fIGF-1 as a
predictive maker for PFS benefit at 3–6 months in PCF-treated patients
(10–20mgkg
 1 F).
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s(ratio of 0.8), 0.03 (ratio of 0.9), 0.01 (ratio of 1) and 0.08 (ratio
of 1.1), respectively, adjusted for multiple testing (Figure 2B).
For PCF10, cutoff criteria of interest were 0.9 (P¼0.04) and
1( P¼0.05). Kaplan–Meier estimates of median PFS in patients
enrolled in Study 1002 who had a baseline insulin/IGFBP-1 ratio
above 0.8 were 2.83 (PC), 3.86 (PC10) and 5.60 months (PC20),
respectively (P¼0.016; Figure 2D–F).
Other potential predictors
Other potential predictors of F activity were investigated. These
included creatinine and creatine clearance, body mass index,
fasting glucose to insulin ratio, the homeostatic model assessment
of insulin sensitivity (HOMA) and the quantitative insulin
sensitivity check index (QUICKI). None of these parameters
reached significance in both the ROC and the Cox biomarker
interaction analyses. A potential interaction with smoking was
investigated using patient reported smoking habits and measuring
pre-treatment cotinine levels, a serum metabolite of nicotine.
Cotinine was detected in 0 of 13 patients who declared to have
never smoke, eight of 61 patients who declared to be ex-smokers
and 12 of 17 smokers. No effect of cotinine levels or smoking status
on the PFS of patients receiving F was identified.
High plasma fIGF-1 is associated with high vimentin and
low E-cadherin expression in NSCLC
We have previously shown that the IGF-IR and other molecules
associated to the IGF-IR pathway (e.g. IGF-2R, IRS-1, -2) are
overexpressed in NSCLC tumours undergoing epithelial-to-
mesenchymal transition (EMT) (Gualberto et al, 2009). Epithe-
lial-to-mesenchymal transition is a key feature of tumour
infiltration and metastasis that is characterised at a molecular
level by the expression of mesenchymal markers, such as vimentin,
and the downregulation of epithelial differentiation markers, such
as E-cadherin (Kalluri and Weinberg, 2009). We hypothesised that
high circulating levels of fIGF-1 could be associated with high IGF
bioactivity in the tumour microenvironment, and this could favour
EMT. As a first step investigating the relationship between fIGF-1
in plasma and tumour EMT, E-cadherin and vimentin levels were
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with baseline fIGF-1 p0.7 (B, N¼64) or 40.7ngml
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 1 (F, N¼48).
Free IGF-1 predicts sensitivity to figitumumab
A Gualberto et al
71
British Journal of Cancer (2011) 104(1), 68–74 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
squantified using F-IHC in tumour biopsies of 45 patients enrolled
in Study 1002. The relationship between circulating fIGF-1 and
tissue marker expression (F-IHC AQUA scores) was investigated
using Pearson’s correlation analysis. Free IGF-1 correlated directly
with tumour vimentin (r¼0.594; P¼0.021), and inversely with
E-cadherin expression (r¼ 0.389; P¼0.152) and the tumour
E-cadherin/vimentin ratio (r¼ 524, P¼0.007). Of note, tumours
in patients who had high levels of circulating fIGF-1 had barely
detectable levels of E-cadherin (Figure 5), suggesting high degree
of tissue de-differentiation.
DISCUSSION
Many targeted therapies are active only for a subset of patients,
and the characterisation of predictive biomarkers to identify those
patients who are likely to benefit has been a key aspect of drug
development. Examples include predicting benefit from trastuzu-
mab therapy in breast cancer by assessing HER2/neu amplification
(Sauter et al, 2009) and from cetuximab in colorectal cancer by
assessing K-ras mutations (Siena et al, 2009). To date, predictive
biomarkers for targeted therapies in NSCLC have been defined
largely in the context of agents that target the EGF receptor family
(Shepherd and Tsao, 2010), although recent data suggest a
predictive value of EML4-ALK gene fusion for the clinical benefit
derived from ALK inhibition (Koivunen et al, 2008). We undertook
the current investigation to identify potential biomarkers that
would allow for the prospective selection of patients who could
benefit from the addition of F to standard chemotherapy
of NSCLC.
Higher pre-treatment fIGF-1 levels were found to be predictive
of the clinical benefit derived from the addition of F to
chemotherapy in NSCLC patients. Although these results require
confirmation in larger studies, it is of interest that consistent with
our results, preliminary data from a recently discontinued phase
III of PCF20 vs PC in patients with non-adenocarcinoma NSCLC
revealed a biomarker/treatment interaction for baseline levels of
fIGF-1. Median overall survival times were 10.2 and 7.0 months,
respectively, for patients with a baseline fIGF1 41ngml
 1
receiving PCF20 and PC alone (Jassem et al, 2010). Analysis of
this phase III study continues and final results will be discussed
elsewhere.
In view of the considerable interindividual heterogeneity in
levels of IGFs and their binding proteins, we hypothesise that
plasma hormone levels might have particular utility in persona-
lised therapy. This is a departure from the more common
paradigm of emphasising molecular characteristics of the tumour
in searching for predictive biomarkers. The reasoning underlying
this hypothesis is that tumours that develop in a patient with high
IGF bioactivity are more likely to become dependent on (or even
‘addicted’ to) IGF-1 receptor signalling, and therefore may be more
sensitive to F therapy. Our results suggest that pre-treatment levels
of fIGF-1 are predictive of the clinical benefit of F therapy in
NSCLC, independent of any tumour characteristics. The possibility
that more precise identification of patients who may benefit from
IGF-IR targeting could be achieved by the use of algorithms that
combines patient hormone levels and tumour characteristics
remains open, but could not be explored in this study owing to
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E-cadherin 100 m
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Figure 5 Cyanine-5 fluorescence images representative of vimentin and E-cadherin expression in tumours from Study 1002 patients. Insets show
cytokeratin (green) and DAPI (blue) fluorescence sample stainings.
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ssmall sample size. We observed however that tumours of patients
with elevated circulating fIGF-1 expressed higher levels of
vimentin and lower levels of E-cadherin, suggesting EMT. We
speculate that this tumour characteristic is secondary to the
hormonal environment. It has been shown previously that IGFs
can induce neo-expression of mesenchymal markers and
E-cadherin downregulation (reviewed by Julien-Grille et al
(2005)). Insulin growth factors have also been shown to enhance
the phosphorylation of b-catenin, causing its dissociation from
membrane E-cadherin and translocation to the cytoplasm/nucleus
(Playford et al, 2000; Morali et al, 2001). These interactions are
thought to facilitate the coupling of IGF-IR activation with
migration, invasiveness and metastasis.
High insulin to IGFBP-1 ratio was also predictive of the clinical
benefit derived from F therapy, and an inverse correlation was
observed between fIGF-1 and IGFBP-1. A role for IGFBP-1 in the
control of IGF-1 bioactivity has been described previously (Bereket
et al, 1996; Attia et al, 1999). Of note, over 90% of serum IGF-1
circulates in a complex with IGFBP-3 and another glycoprotein,
acid-labile subunit (ALS). This complex is large (150kDa), unable
to transverse the endothelial barrier and has a long half-life, acting
as a serum reservoir of IGF-1 (Kelley et al, 1996). In contrast, IGF-1
bound to IGFBP-1 does not form complexes with ALS, is able to
cross the endothelial barrier and is, consequently, more likely to
play a role in the regulation of IGF-1 bioactivity at extravascular
tissues (Lee et al, 1993).
Insulin growth factor binding protein-1 levels and its IGF-1
binding capacity are tightly regulated by insulin, with IGFBP-1, as
a result, acting as a bridging molecule between the insulin and IGF
systems (Sakai et al, 2001; Borai et al, 2007). Thus, our data suggest
that insulin may affect the risk/benefit of anti-IGF-IR therapy by
regulating fIGF-1 levels. This is not in contradiction with other
potential effects of insulin on cancer therapy; for example, those
mediated by insulin receptors on tumour cells (Gualberto and
Pollak, 2009). A role for IGFBP-1 in cancer has not been
extensively studied, but it is known that low IGFBP-1 levels are
associated with poor prognosis in at least one tumour type,
colorectal cancer (Wolpin et al, 2009). Further research on IGFBP-
1 functions could contribute to a better understanding of the
effects of carbohydrate metabolism on cancer outcome. Overall,
our data are consistent with previous reports associating low IGF-1
bioactivity with longer overall, disease-free and event-free survival
in NSCLC (Chang et al, 2002; Han et al, 2006). In principle, the
utilisation of circulating factors as predictive biomarkers would
appear to be more convenient than measurements requiring fresh
or frozen neoplastic tissue. However, it should be noted that
current assay methodologies, particularly those measuring IGF-1
bioactivity, are controversial and imperfect (Frystyk, 2007). For
example, in some applications, measurement of fIGF-1 offers no
additional information beyond that provided by total IGF-1 (Juul
et al, 1997), a measurement which is much more widely used than
fIGF-1, but that is itself challenging (Brugts et al, 2008a). This issue
is further complicated by the relatively small fraction of total IGF-1
bound to IGFBP-1 (Attia et al, 1999). In our hands, the fIGF-1
assay had an intra-assay imprecision of approximately 10% at the
criteria of interest (0.5–0.9ngml
 1); however, differences were
observed across reagent lots. Thus, further analytical validation
would be desirable before the prospective use of this assay in
randomised studies. Structural studies have recently shown that
the binding residues for IGFBP-1 and -3 on IGF-1 are overlapping
but distinct (Dubaquie ´ and Lowman 1999; Dubaquie ´ et al, 2001).
These differences could be exploited to develop new assays for the
quantification of the fIGF-1 fraction specifically released from
IGFBP-1. Development of such reagents could be important for a
more personalised use of anti-IGF-IR therapy.
This exploratory study was not sufficiently powered for subset
safety analysis. No major differences in the frequency or severity of
adverse events between subgroups of patients with low vs high
baseline fIGF-1 were apparent (not shown). Low levels of IGF-1
bioactivity have been associated with increased risk of cardiovas-
cular mortality, whereas fasting IGFBP-1 levels were associated
with more favourable cardiovascular risk profiles (Janssen et al,
1998; Brugts et al, 2008b). Of note, IGF-1 bioactivity changes
during the progression of the metabolic syndrome, increasing in
parallel to HOMA-IR and hyperinsulinaemia, but decreasing
drastically when patients reach frank diabetes (Brugts et al,
2010). Insulin growth factor-1 bioactivity is also limited at low total
IGF-1 levels (Brugts et al, 2010). Thus, treatment with anti-IGF-IR
therapy in patients with low levels of total IGF-1 and/or glucose
intolerance should be approached with caution. The ongoing
analysis of the safety profile of larger F studies may contribute to a
better understanding of the potential role of fIGF-1 in the
assessment of the risk/benefit of anti-IGF-IR therapy.
In conclusion, our data provide preliminary evidence that
fIGF-1 is a predictive biomarker of the clinical benefit, in terms of
PFS, of F therapy in NSCLC. Confirmation of these findings
in larger studies is needed. We also recognise the need to optimise
assay methods and to further study the interactions between
serum markers and tumour characteristics in NSCLC and other
cancer types in which IGF-IR targeting is currently being
investigated.
ACKNOWLEDGEMENTS
We thank our patients for their participation in this trial. This
work was supported in part by NIH PHS Grants ES015704 (to
MLH), and by Pfizer Inc.
REFERENCES
Attia N, Caprio S, Jones TW, Heptulla R, Holcombe J, Silver D, Sherwin RS,
Tamborlane WV (1999) Changes in free insulin-like growth factor-1 and
leptin concentrations during acute metabolic decompensation in insulin
withdrawn patients with type 1 diabetes. J Clin Endocrinol Metab 84:
2324–2328
Bereket A, Lang CH, Blethen SL, Ng LC, Wilson TA (1996) Insulin
treatment normalizes reduced free insulin-like growth factor-I concen-
trations in diabetic children. Clin Endocrinol (Oxf) 45: 321–326
Borai A, Livingstone C, Ferns GA (2007) The biochemical assessment of
insulin resistance. Ann Clin Biochem 44: 324–342
Brugts MP, Ranke MB, Hofland LJ, van der Wansem K, Weber K, Frystyk J,
Lamberts SW, Janssen JA (2008a) Normal values of circulating insulin-
like growth factor-I bioactivity in the healthy population: comparison
with five widely used IGF-1 immunoassays. J Clin Endocrinol Metab 93:
2539–2545
B r u g t sM P ,v a nd e nB e l dA W ,H o f l a n dL J ,v a nd e rW a n s e mK ,v a nK o e t s v e l d
PM, Frystyk J, Lamberts SW, Janssen JA (2008b) Low circulating insulin-
like growth factor I bioactivity in elderly men is associated with increased
mortality. J Clin Endocrinol Metab 93: 2515–2522
Brugts MP, van Duijn CM, Hofland LJ, Witteman JC, Lamberts SW, Janssen JA
(2010) Igf-I bioactivity in an elderly population: relation to insulin
sensitivity, insulin levels, and the metabolic syndrome. Diabetes 59: 505–508
Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee
HY (2002) Clinical significance of insulin-like growth factor-binding
protein-3 expression in stage I non-small cell lung cancer. Clin Cancer
Res 8: 3796–3802
Free IGF-1 predicts sensitivity to figitumumab
A Gualberto et al
73
British Journal of Cancer (2011) 104(1), 68–74 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sChitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM (2008) The
type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14:
6364–6370
Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE,
Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005)
Combination therapy enhances the inhibition of tumor growth with the
fully human anti-type 1 insulin-like growth factor receptor monoclonal
antibody CP-751,871. Clin Cancer Res 11: 2063–2073
Dubaquie ´ Y, Lowman HB (1999) Total alanine-scanning mutagenesis of
insulin-like growth factor I (IGF-1) identifies differential binding
epitopes for IGFBP-1 and IGFBP-3. Biochemistry 38: 6386–6396
Dubaquie ´ Y, Mortensen DL, Intintoli A, Hogue DA, Nakamura G,
Rancatore P, Lester P, Sadick MD, Filvaroff E, Fielder PJ, Lowman HB
(2001) Binding protein-3-selective insulin-like growth factor I variants:
engineering, biodistributions, and clearance. Endocrinology 142:
165–173
Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A,
Noonan D, Biassoni R (1994) Expression and function of the insulin like
growth factor 1 system in human non small cell lung cancer and normal
lung cell lines. Int J Cancer 56: 858–866
Frystyk J (2007) Utility of free IGF-1 measurements. Pituitary 10: 181–187
Gualberto A (2010) Figitumumab (CP-751,871) for cancer therapy.
Expert Opin Biol Ther 10: 575–585
Gualberto A, Dolled-Filhart MP, Hixon ML, Christensen J, Rimm DL,
Lee AV, Wang Y, Pollak M, Paz-Ares LG, Karp DD (2009) Molecular
basis for sensitivity to figitumumab (CP-751,871) in NSCLC. J Clin Oncol
27: 15s (abstract 8091)
Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor
receptor inhibitors in oncology: early clinical trial results and future
directions. Oncogene 28: 3009–3021
Han JY, Choi BG, Choi JY, Lee SY, Ju SY (2006) The prognostic significance
of pretreatment plasma levels of insulin-like growth factor (IGF)-1,
IGF-2, and IGF binding protein-3 in patients with advanced non-small
cell lung cancer. Lung Cancer 54: 227–234
Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW (1998) Serum
total IGF-1, free IGF-1, and IGFB-1 levels in an elderly population:
relation to cardiovascular risk factors and disease. Arterioscler Thromb
Vasc Biol 18: 277–282
Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K,
Novello S, Strausz J, Gualberto A (2010) Randomized, open label, phase
III trial of figitumumab in combination with paclitaxel and carboplatin
versus paclitaxel and carboplatin in patients with non-small cell lung
cancer (NSCLC). J Clin Oncol 28: 15s (abstract 7500)
Julien-Grille S, Moore R, Denat L, Morali OG, Delmas V, Bellacosa A,
Laure L (eds) (2005) The role of insulin-like growth factors in the epithelial
to mesenchymal transition. In: Rise and Fall of Epithelial Phenotype:
Concepts of Epithelial. Eurekah/Landes Bioscience: Georgetown
Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T,
Rasmussen S, Mu ¨ller J, Skakkebaek NE (1997) Free insulin-like growth
factor I serum levels in 1430 healthy children and adults, and its
diagnostic value in patients suspected of growth hormone deficiency.
J Clin Endocrinol Metab 82: 2497–2502
Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal
transition. J Clin Invest 119: 1420–1428
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F,
Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein Jr G, Johnson FM,
Green S, Gualberto A (2009) Phase II study of the anti-insulin-like
growth factor type 1 receptor antibody CP-751,871 in combination
with paclitaxel and carboplatin in previously untreated, locally
advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:
2516–2522
Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L,
Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding
proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol
28: 619–637
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ,
Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker
DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C,
Meyerson M, Ja ¨nne PA (2008) EML4-ALK fusion gene and efficacy of an
ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275–4283
Lee PD, Conover CA, Powell DR (1993) Regulation and function of insulin-
like growth factor binding protein-1. Proc Soc Exp Biol Med 204: 4–29
Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L (2001) IGF-2
induces rapid beta-catenin relocation to the nucleus during epithelium to
mesenchyme transition. Oncogene 20: 4942–4950
Sakai K, D’Ercole AJ, Murphy LJ, Clemmons DR (2001) Physiological
differences in insulin-like growth factor binding protein-1 (IGFBP-1)
phosphorylation in IGFBP-1 transgenic mice. Diabetes 50: 32–38
Playford MP, Bicknell D, Bodmer WF, Macaulay VM (2000) Insulin-like
growth factor 1 regulates the location, stability, and transcriptional
activity of beta-catenin. Proc Natl Acad Sci USA 9: 12103–12108
Pollak M (2008) Insulin and insulin-like growth factor signalling in
neoplasia. Nat Rev Cancer 8: 915–928
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009)
Biomarkers predicting clinical outcome of epidermal growth factor
receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer
Inst 101: 1308–1324
Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for
human epidermal growth factor receptor 2 testing: biologic and
methodologic considerations. J Clin Oncol 27: 1323–1333
Shepherd FA, Tsao MS (2010) Epidermal growth factor receptor
biomarkers in non-small-cell lung cancer: a riddle, wrapped in a
mystery, inside an enigma. J Clin Oncol 28: 903–905
Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M
(2002) Serum insulin like growth factor (IGF) and IGF binding protein
levels and risk of lung cancer: a case control study nested in the beta
carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers
Prev 11: 1413–1418
Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN,
Giovannucci EL, Fuchs CS (2009) Insulin, the insulin-like growth factor
axis, and mortality in patients with nonmetastatic colorectal cancer. 27:
176–185
Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots:
a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561–577
Free IGF-1 predicts sensitivity to figitumumab
A Gualberto et al
74
British Journal of Cancer (2011) 104(1), 68–74 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s